Finance

Beta
Lists
ENGN:NASDAQ
enGene Therapeutics Inc
$1.75
+2.34%
(+0.040) 1D
$1.74
-0.57% (-0.0100)
Pre-market
Closed: Jun 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ENGN...
Open
$1.71
High
$1.83
Low
$1.70
Mkt. cap
117.92M
Avg. vol.
1.66M
Volume
0.00
52-wk high
$12.25
52-wk low
$1.40
EPS
-$2.18
Beta
-0.29
Shares outstanding
66.99M
No. of employees
82
Open
$1.71
High
$1.83
Low
$1.70
Mkt. cap
117.92M
Avg. vol.
1.66M
Volume
0.00
52-wk high
$12.25
52-wk low
$1.40
EPS
-$2.18
Beta
-0.29
Shares outstanding
66.99M
No. of employees
82
News stories
From sources across the web
About enGene Therapeutics Inc
CEO-
Employees82
Founded-
Headquarters-
SectorBiotechnology
Websiteengene.com
Analyst Ratings
Based on 10 analysts giving stock ratings to ENGN in the past 3 months
Hold
Buy
3
Hold
6
Sell
1
12 month forecast
Based on 10 Wall Street analysts offering 12 month price targets for ENGN in the last 3 months.
Highest
Current $1.75
$21.50 (+1,128.57%)
Average
$5.64 (+222.29%)
Lowest
$2.00 (+14.29%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Judah Frommer
Morgan Stanley
Sell
Downgraded
-
-
06/18/2026
Michael Schmidt
Guggenheim
Hold
Maintained
-
-
06/16/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Maintained
$4.00
+128.6%
06/16/2026
Yanan Zhu
Wells Fargo
Hold
Reiterated
$2.00
+14.3%
06/15/2026
David Dai
UBS
Hold
Maintained
$2.00
+14.3%
05/14/2026
Mani Foroohar
Leerink Partners
Hold
Downgraded
$2.00
+14.3%
05/08/2026
Leland Gershell
Oppenheimer
Hold
Maintained
-
-
05/08/2026
Sean McCutcheon
Raymond James
Buy
Maintained
$4.00
+128.6%
05/08/2026
Allison Bratzel
Piper Sandler
Hold
Downgraded
$4.00
+128.6%
05/08/2026
Silvan Tuerkcan
Citizens JMP
Hold
Downgraded
-
-
05/08/2026
Unknown Analyst
WBB Securities
Buy
Initiated
$21.50
+1,128.6%
04/13/2026
Xin Yang NG‏
USmart Securities
Buy
Initiated
$21.50
+1,128.6%
04/13/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
-
-
03/26/2026
Maury Raycroft
Jefferies
Buy
Maintained
$28.00
+1,500%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jul 2025
Oct 2025
Jan 2026
Apr 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
22.58M
31.72M
22.26M
22.20M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.37M
7.76M
8.93M
9.77M
Operating expense
29.95M
39.48M
31.18M
31.97M
Total operating expenses
29.95M
39.48M
31.18M
31.97M
Operating income
-29.95M
-39.48M
-31.18M
-31.97M
Other non operating income
-280.00K
448.00K
-
-
EBT including unusual items
-28.75M
-38.38M
-29.75M
-30.23M
EBT excluding unusual items
-28.75M
-38.38M
-29.26M
-30.23M
Income tax expense
239.00K
-497.00K
-
-
Effective tax rate
-0.83%
1.29%
-
-
Other operating expenses
-
-
-
-
Net income
-28.99M
-37.88M
-29.75M
-30.23M
Net profit margin
-
-
-
-
Earnings per share
-0.57
-0.73
-0.44
-0.43
Interest and investment income
2.23M
1.98M
2.74M
2.66M
Interest expense
-758.00K
-750.00K
-732.00K
-745.00K
Net interest expenses
1.48M
1.22M
2.01M
1.92M
Depreciation and amortization charges
-
-
-
-
EBITDA
-29.82M
-39.31M
-31.00M
-31.79M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer